PBYIPuma Biotechnology, Inc.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.
Priced for a decline (~−1% a year). The price bakes in little to no growth.
Expensive vs its own history: P/E 19.2 vs a 10.3 median over 14 quarters (+87% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PBYI's price assumes
Puma Biotechnology, Inc. trades at 19.2× earnings against 18.6× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 18.6 · 1.03× the median: the market pays up for this one
- Price / sales
- 1.43
Price / sales · as of 2026-Q1
- Free cash flow yield
- 8.1%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- −0.76%
Growth the price implies · The price pays for −0.76% free cash flow growth a year for a decade; revenue has grown +0.16% a year over the last three.
Details›
- Price / bookas of 2026-Q1
- 2.53
- EV / EBITas of 2026-Q1
- 10.3
- EV / salesas of 2026-Q1
- 1.34
- Healthcare median P/E509 names
- 26.0
- Biotechnology median P/E244 names
- 18.6
- Free cash flow, trailing twelve months
- $41M
- Market capitalisation
- $508M
- 3-year revenue growth
- +0.16%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $3.04 |
| Its own P/E history, median | $5.34 |
| Its own P/E history, upper quartile | $8.49 |
| 52-week range | $4.73 – $9.98 |
| Today | $9.98 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.